NO995753D0 - Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament - Google Patents

Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament

Info

Publication number
NO995753D0
NO995753D0 NO995753A NO995753A NO995753D0 NO 995753 D0 NO995753 D0 NO 995753D0 NO 995753 A NO995753 A NO 995753A NO 995753 A NO995753 A NO 995753A NO 995753 D0 NO995753 D0 NO 995753D0
Authority
NO
Norway
Prior art keywords
controlled release
drug administration
improved drug
release gastro
retardant microspheres
Prior art date
Application number
NO995753A
Other languages
English (en)
Norwegian (no)
Other versions
NO995753L (no
Inventor
Lisbeth Illum
He Ping
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Publication of NO995753D0 publication Critical patent/NO995753D0/no
Publication of NO995753L publication Critical patent/NO995753L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO995753A 1997-05-24 1999-11-24 Gastroretarderende mikrosfærer med styrt frigivelse for bedret administrasjon av medikament NO995753L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9710699.1A GB9710699D0 (en) 1997-05-24 1997-05-24 Gastro-retentive controlled release system
PCT/GB1998/001513 WO1998052547A1 (en) 1997-05-24 1998-05-22 Gastroretentive controlled release microspheres for improved drug delivery

Publications (2)

Publication Number Publication Date
NO995753D0 true NO995753D0 (no) 1999-11-24
NO995753L NO995753L (no) 1999-11-24

Family

ID=10812970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995753A NO995753L (no) 1997-05-24 1999-11-24 Gastroretarderende mikrosfærer med styrt frigivelse for bedret administrasjon av medikament

Country Status (22)

Country Link
US (1) US6207197B1 (pt)
EP (1) EP0984774B1 (pt)
JP (1) JP2001525848A (pt)
KR (1) KR20010012857A (pt)
CN (1) CN1257425A (pt)
AR (1) AR012854A1 (pt)
AT (1) ATE270880T1 (pt)
AU (1) AU737818B2 (pt)
BR (1) BR9809453A (pt)
CA (1) CA2285580A1 (pt)
DE (1) DE69825049T2 (pt)
ES (1) ES2226137T3 (pt)
GB (2) GB9710699D0 (pt)
HU (1) HUP0002935A3 (pt)
IL (1) IL132453A0 (pt)
NO (1) NO995753L (pt)
NZ (1) NZ338105A (pt)
PL (1) PL336037A1 (pt)
PT (1) PT984774E (pt)
SK (1) SK148999A3 (pt)
WO (1) WO1998052547A1 (pt)
ZA (1) ZA984379B (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
WO2000047644A1 (en) * 1999-02-12 2000-08-17 Universiteit Gent A biocompatible adhesive system and a bioadhesive drug delivery system with controllable release
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
DE59908471D1 (de) * 1999-07-02 2004-03-11 Cognis Iberia Sl Mikrokapseln - II
ES2247749T3 (es) 1999-07-02 2006-03-01 Cognis Ip Management Gmbh Microcapsulas iii.
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
ES2375269T3 (es) * 2000-12-07 2012-02-28 Nycomed Gmbh Preparado farmacéutico en forma de una pasta que comprende un ingrediente activo l�?bil ante los �?cidos.
KR100413114B1 (ko) * 2001-03-30 2003-12-31 재단법인서울대학교산학협력재단 키토산으로 표면 코팅된 조직 재생용 생분해성 고분자제제 및 그 제조방법
EP1245227A1 (en) 2001-03-31 2002-10-02 Jagotec Ag A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
WO2003045308A2 (en) * 2001-11-21 2003-06-05 E-Z-Em, Inc. Formulations for use in medical or diagnostic procedures
AU2003205106A1 (en) * 2002-01-16 2003-09-02 Agency For Disease Diagnosis And Prevention Pace-a microspheres for delivery of antigens
WO2003072014A2 (en) 2002-02-25 2003-09-04 Mpex Bioscience, Inc. Minicell compositions and methods
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004021798A1 (es) * 2002-09-03 2004-03-18 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Metodo de preparacion de microcapsulas de astaxantina en quitosano y producto obtenido
US8986737B2 (en) * 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
US20040131681A1 (en) * 2002-09-05 2004-07-08 Ambrose Catherine G. Antibiotic microspheres for treatment of infections and osteomyelitis
CA2506807A1 (en) * 2002-12-13 2004-07-01 Cilag Ag Controlled release preparations comprising tramadol and topiramate
EP1587499A1 (en) * 2003-01-31 2005-10-26 Elan Pharma International Limited Nanoparticulate topiramate formulations
CN1212837C (zh) * 2003-07-02 2005-08-03 南京天泽医药科技开发有限公司 雷尼替丁微丸制剂
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
GB0427455D0 (en) * 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
KR100815040B1 (ko) * 2005-01-31 2008-03-18 주식회사종근당 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물
WO2006110889A2 (en) * 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
US8865197B2 (en) * 2005-09-06 2014-10-21 Israel Oceanographic And Limnological Research Ltd. Food formulation for aquatic animals with integrated targeted delivery of bioactive agents
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
CA2675230A1 (en) * 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
JP5004505B2 (ja) * 2006-05-18 2012-08-22 株式会社サンギ 口腔用組成物
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
WO2008010690A1 (en) * 2006-07-21 2008-01-24 Handok Pharmaceuticals Co., Ltd. Gastric retention-type pellet and the preparation method thereof
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US8178483B2 (en) * 2007-03-30 2012-05-15 Colgate-Palmolive Company Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
AU2008306688B2 (en) 2007-10-03 2014-05-22 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
KR101623999B1 (ko) 2008-06-25 2016-05-24 벡션 테라퓨틱스 엘엘씨 조절된 유전자 자살 메커니즘 조성물 및 방법
CN102307574A (zh) 2008-10-08 2012-01-04 鲍斯生命科学Pvt有限公司 缓释给药系统
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102573809B (zh) 2009-07-31 2017-07-21 格兰泰股份有限公司 结晶方法和生物利用度
WO2011111068A2 (en) 2010-03-09 2011-09-15 Council Of Scientific And Industrial Research Gastroretentive, extended release composition of therapeutic agent
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
ES2720659T3 (es) 2011-02-15 2019-07-23 Vaxiion Therapeutics Llc Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos
WO2012171125A1 (en) 2011-06-13 2012-12-20 Rival, Société En Commandite N,n,n-trialkylpolymers, methods of their preparation and uses thereof
AU2012322323B2 (en) 2011-10-11 2016-04-21 Sun Pharmaceutical Industries Limited A gastroretentive dosage system and process of preparation thereof
EA027186B1 (ru) * 2011-12-09 2017-06-30 Юнилевер Н.В. Антимикробная композиция
EP2844301A2 (en) 2012-05-04 2015-03-11 Ineb-instituto de Engenharia Biomédica Microspheres for treating helicobacter pylori infections
SG11201500227SA (en) * 2012-08-16 2015-02-27 Univ Nanyang Tech Floating capsules encapsulating particles loaded with one or more drugs
CN113577260A (zh) 2012-10-02 2021-11-02 瓦克星治疗有限责任公司 免疫调节性小细胞及使用方法
US9861585B2 (en) 2012-10-16 2018-01-09 Sun Pharmaceutical Industries Limited Osmotic floating tablets
KR101486132B1 (ko) * 2013-03-20 2015-01-23 씨제이헬스케어 주식회사 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구
CN105916493A (zh) 2013-12-06 2016-08-31 高级生物营养公司 用于经口递送生物活性剂的组合物
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
EP3240527B1 (en) 2014-12-31 2019-09-25 Tihminlioglu, Funda Essential oil loaded mucoadhesive nanocomposite delivery system for gastrointestinal system
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
EP3331575A4 (en) 2015-08-04 2019-03-27 Vaxiion Therapeutics, LLC STERILIZATION USING IONIZING RADIATION OF BIOPHARMAZEUTIKA BASED ON BACTERIAL MINIMIZES AND METHODS OF USE
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
EP3432877B1 (en) 2016-03-24 2023-01-11 ImmunoMolecular Therapeutics, Inc. D-alpha-methyldopa for treating autoimmune disease
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN106389386A (zh) * 2016-09-13 2017-02-15 温州生物材料与工程研究所 一种用于药物包载与缓释的生物相容性交联微纳米材料及其构建工艺
US11167008B2 (en) 2016-11-23 2021-11-09 Vaxiion Therapeutics, Llc Immunomodulatory and oncolytic minicells and methods of use
EP3615659A4 (en) 2017-04-28 2021-01-06 Agrospheres, Inc. COMPOSITIONS AND METHODS OF ENCAPSULATION AND SCALABLE DELIVERY OF AGROCHEMICALS
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
SG11202004336VA (en) 2017-12-01 2020-06-29 Ultragenyx Pharmaceutical Inc Creatine prodrugs, compositions and methods of use thereof
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
CN114191307A (zh) 2020-09-17 2022-03-18 上海汉都医药科技有限公司 一种口腔滞留装置及其制备方法
WO2019223753A1 (zh) 2018-05-23 2019-11-28 上海汉都医药科技有限公司 活性药物成分的控释系统及其制备方法
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
CN114376087A (zh) * 2022-02-24 2022-04-22 北京九州大地生物技术集团股份有限公司 一种改善公牛繁育性能的高锌饲料添加剂及制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
JPS62195323A (ja) 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
JPH0623202B2 (ja) 1986-07-11 1994-03-30 大日精化工業株式会社 キトサン粒体の製造方法
CA2014244A1 (en) 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
US5196409A (en) * 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
JP3334879B2 (ja) 1991-04-15 2002-10-15 アンビー インコーポレイテッド 抗胃障害製剤組成物
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5198229A (en) 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
JPH05339149A (ja) 1992-02-27 1993-12-21 Taisho Pharmaceut Co Ltd 徐放性懸濁製剤
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
SE9201930D0 (sv) * 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Composition of microspheres with several delayed release nuclei and its preparation process.
ES2068762B1 (es) * 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter

Also Published As

Publication number Publication date
AR012854A1 (es) 2000-11-22
GB9710699D0 (en) 1997-07-16
HUP0002935A2 (hu) 2000-12-28
ES2226137T3 (es) 2005-03-16
GB9926405D0 (en) 2000-01-12
HUP0002935A3 (en) 2001-04-28
PT984774E (pt) 2004-11-30
US6207197B1 (en) 2001-03-27
SK148999A3 (en) 2000-07-11
NZ338105A (en) 2001-04-27
NO995753L (no) 1999-11-24
JP2001525848A (ja) 2001-12-11
CN1257425A (zh) 2000-06-21
AU737818B2 (en) 2001-08-30
ATE270880T1 (de) 2004-07-15
WO1998052547A1 (en) 1998-11-26
GB2341550B (en) 2002-01-09
BR9809453A (pt) 2000-06-20
EP0984774B1 (en) 2004-07-14
KR20010012857A (ko) 2001-02-26
DE69825049T2 (de) 2005-07-21
AU7664298A (en) 1998-12-11
ZA984379B (en) 1999-11-22
EP0984774A1 (en) 2000-03-15
PL336037A1 (en) 2000-06-05
CA2285580A1 (en) 1998-11-26
GB2341550A (en) 2000-03-22
DE69825049D1 (de) 2004-08-19
IL132453A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
NO995753D0 (no) Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament
NO20002977D0 (no) Terapeutisk formulering for administrasjon av tolterodin med kontrollert frigivelse
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DK1043976T3 (da) Oral farmaceutisk doseringsform med langvarig frigivelse
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
IS5245A (is) Lyfjablanda úr ómeprasól
DK0840634T3 (da) Transcornealt lægemiddelfrigivelsessystem
HUP0301242A3 (en) Controlled release drug dosage form
NO20000735L (no) Legemiddel leveringsanordning for vedvarende frigivelse
NO20014035D0 (no) System for oral administrasjon av medikament
BR9607752B1 (pt) formulação farmacêutica de microcápsula de liberação controlada.
PL336759A1 (en) Controllable release of drugs administered by holding them beneath the tongue or behind the bucca
DE69829254D1 (de) Arzneistoffzubereitung mit kontrollierter Wirkstofffreisetzungsrate
TR200000534A3 (tr) Bir ilacin uygulanmasi için metot ve sistem
NO996372L (no) Fast farmasøytisk preparat inneholdende benzofuanderivater
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
NO20002126L (no) Formulering med forlenget frigjøring
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
NO996044L (no) Rapamycinformuleringer for oral administrasjon
DK0984774T3 (da) Mikrosfærer med gastroretentivt reguleret frigivelse til forbedret lægemiddelafgivelse
NO994140D0 (no) Farmasöytisk sammensetning for den programerte frigivelse av deksfenfluramin
DE10081277D2 (de) Kapsel mit kontrollierter Wirkstofffreisetzung
NO20003284L (no) Farmasøytisk preparat for oral administrering
FI950008A (fi) Farmaseuttinen koostumus kontrolloitua vapautumista varten
BR9612652A (pt) Forma de administração farmacêutica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application